Lee's Pharmaceutical Holdings Ltd is an investment holding company principally engaged in the development, manufacturing, marketing and sales of pharmaceutical products. The Company operates its business through two segments. The Imported Products segment is engaged in the sale of imported products. Its imported products include Keyan injection, Fipril oral solution and others. The Proprietary Products segment is engaged in the manufacture and sale of self-developed products. Its R&D products include Resilicon Tablets, ADASUVE Inhalation Powder and others. The Company's medicines cover the fields of cardiovascular and infectious diseases, dermatology, oncology, gynecology and ophthalmology. The Company mainly operates its business in mainland China, Hong Kong and Taiwan.

Employees

1,094

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-08-03	HK$1.070	0.00%	159,000
26-07-31	HK$1.070	+1.90%	342,500
26-07-30	HK$1.050	-2.78%	897,000
26-07-29	HK$1.080	+1.89%	492,500
26-07-28	HK$1.060	-6.19%	1,996,500

Delayed Quote Hong Kong S.E.

More quotes

Income Statement and Estimates

More financial data

Net sales - Rate of surprise

Company calendar

Market Closed - Hong Kong S.E. Other stock markets 04:08:12 2026-08-03 EDT			5-day change	1st Jan Change
1.070 ^HKD	0.00%		-7.76%	-29.61%

07-30	Ashlins Obtains Exclusive Rights to Develop and Commercialize Certain Drug Products Incorporating Lee's Pharm's Interferon	CI
07-17	Lee?s Pharmaceutical Holdings Limited Enters into Exclusive License-Out and Supply Agreement with Ashlins Ocular Pharmaceuticals, Inc. for Interferon Alpha-2B Products Outside Greater China	CI

Market Cap	630M 80.34M 69.83M 65.19M 59.85M 113M 7.66B 115M 769M 301M 3.82B 302M 295M 12.6B	P/E 2024	8.98x	P/E 2025	9.74x
Enterprise Value	590M 75.29M 65.43M 61.09M 56.08M 106M 7.18B 108M 720M 282M 3.58B 283M 277M 11.8B	EV / Sales 2024	0.6x	EV / Sales 2025	0.6x
Free-Float	50.73%	Yield 2024	3.17%	Yield 2025	2.96%

07-30	Ashlins Obtains Exclusive Rights to Develop and Commercialize Certain Drug Products Incorporating Lee's Pharm's Interferon	CI
07-17	Lee?s Pharmaceutical Holdings Limited Enters into Exclusive License-Out and Supply Agreement with Ashlins Ocular Pharmaceuticals, Inc. for Interferon Alpha-2B Products Outside Greater China	CI
06-17	Lee's Pharmaceutical Launches HK$50 Million Share Buyback; Shares Jump 8%	MT
06-01	Lee's Pharmaceutical to Receive Gates Foundation Funding	MT
05-11	Lee's Pharmaceutical says Zhaoke Hefei to contribute RMB25 million to partnership fund	RE
03-30	Lee's Pharmaceutical Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-30	Lee's Pharmaceutical declares final dividend of HK2.3 cents per share	RE
03-30	Lee's Pharmaceutical Holdings Limited Recommends Final Dividend for the Year Ended December 31, 2025, Payable on June 15, 2026	CI
03-25	Lee's Pharmaceutical reports approval of Intrarosa by NMPA	RE
01-27	Lee's Pharmaceutical Receives Regulatory Nod to Move Production of Drug Within U.S.	MT
01-27	Lee's Pharmaceutical receives FDA approval of supplemental new drug application for Adasuve	RE
01-27	Lee's Pharmaceutical Holdings Limited Announces U.S. Food and Drug Administration Approval of Supplemental New Drug Application for ADASUVE	CI
01-23	Solasia Pharma Signs New Partner to Market and Manufacture Sancuso in China	MT

22-05-18	Sorrento Therapeutics' License Partner, Lee's Pharm, Announces Full Enrollment of 498 Patients in a Phase III Trial of Socazolimab (Anti-PD-L1 Antibody) for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)	AQ
21-12-31	Listing on Guidance for Family Choice Pharmacy of Lee's Pharm signature products, Ferplex and Yallaferon	AQ
21-11-01	Sorrento’s License Partner, Lee’s Pharmaceutical Announces NDA Filing Acceptance by NMPA for Anti-PD-L1 Antibody Socazolimab for Treatment of Recurrent or Metastatic Cervical Cancer	AQ
21-05-14	Lee Pharmaceutical : Notice of Board Meeting	PU
21-04-28	Lee Pharmaceutical : (1) Establishment of Management Committee; (2) Resignation of Chief Executive Officer and Re-designation of Director; and (3) Change of Authorised Representative	PU

Lee's Pharmaceutical Holdings Limited Stock

Stocks

950

KYG5438W1116

Pharmaceuticals

Valuation: Lee's Pharmaceutical Holdings Limited

Chart: Lee's Pharmaceutical Holdings Limited

Latest news : Lee's Pharmaceutical Holdings Limited

Press Releases: Lee's Pharmaceutical Holdings Limited

Quotes and Performance

Course Extremes

Managers and Directors: Lee's Pharmaceutical Holdings Limited

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Net sales - Rate of surprise

1 week	-7.76%
1 month	+2.88%
3 months	-4.46%
6 months	-30.97%
Current year	-29.61%

1 week	1.04	1.14
1 month	1.02	1.19
Current year	0.99	1.69
1 year	0.99	2.7
3 years	0.99	2.7
5 years	0.99	4.3
10 years	0.99	14.7

Manager	Title	Age	Since
Wanee Leelalertsuphakun CEO	Chief Executive Officer	73	1997-03-31
Yiu Ming Chow DFI	Director of Finance/CFO	53	2014-10-06
Sze Ka Wong CTO	Chief Tech/Sci/R&D Officer	44	-

Director	Title	Age	Since
Siu Fong Lee CHM	Chairman	70	2010-04-04
Wanee Leelalertsuphakun BRD	Director/Board Member	73	2001-11-30
Xiao Yi Li BRD	Director/Board Member	63	2003-08-31

Date	Insider	Type	Main position	Quantity	% Market Cap.
10/15/25	Huby Technology Ltd.	Other	Company	588,000	0.0999%
10/15/25	Xiao Yi Li	Other	Founder	588,000	0.0999%
10/15/25	Wanee Leelalertsuphakun	Other	Chief Executive Officer	588,000	0.0999%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LEE'S PHARMACEUTICAL HOLDINGS LIMITED	0.00%	-7.76%	-38.15%	-25.17%	80.35M
ELI LILLY AND COMPANY	-2.39%	-6.36%	+47.10%	+149.66%	1,024B
JOHNSON & JOHNSON	-0.76%	-4.34%	+52.04%	+49.09%	618B
ABBVIE INC.	-2.33%	-4.60%	+25.55%	+64.44%	443B
ROCHE HOLDING AG	+0.68%	+0.25%	+38.47%	+31.95%	349B
NOVARTIS AG	-1.66%	-1.89%	+32.18%	+37.17%	297B
ASTRAZENECA PLC	-8.96%	-9.23%	+3.57%	+3.64%	264B
NOVO NORDISK A/S	-1.37%	-5.71%	-2.10%	-44.43%	209B
AMGEN INC.	-1.63%	+0.69%	+27.62%	+64.23%	208B
GILEAD SCIENCES, INC.	+0.72%	+0.48%	+15.88%	+73.64%	162B
Average	-1.38%	-1.99%	+20.21%	+40.42%	357.38B
Weighted average by Cap.	-0.98%	-2.17%	+34.56%	+70.33%

	2024	2025
Net sales	1.4B 179M 155M 145M 133M 251M 17.02B 255M 1.71B 669M 8.49B 671M 656M 27.99B	1.44B 183M 159M 149M 136M 257M 17.45B 262M 1.75B 686M 8.7B 688M 673M 28.71B
Net income	93.1M 11.87M 10.32M 9.63M 8.84M 16.67M 1.13B 16.96M 114M 44.48M 564M 44.59M 43.6M 1.86B	91.94M 11.72M 10.19M 9.51M 8.73M 16.47M 1.12B 16.75M 112M 43.93M 557M 44.04M 43.06M 1.84B
Net Debt	10.45M 1.33M 1.16M 1.08M 993K 1.87M 127M 1.9M 12.75M 4.99M 63.36M 5.01M 4.9M 209M	-39.63M -5.05M -4.39M -4.1M -3.76M -7.1M -482M -7.22M -48.35M -18.94M -240M -18.98M -18.56M -792M